Comparative Pharmacology
Head-to-head clinical analysis: BELDIN versus PROMETHACON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELDIN versus PROMETHACON.
BELDIN vs PROMETHACON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
1 capsule (200 mg) orally every 12 hours.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
None Documented
None Documented
Terminal half-life: 8-12 hours (average 10 hours); prolonged in hepatic impairment (up to 24 h) and severe renal impairment (up to 18 h).
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Renal: 30-50% unchanged; hepatic metabolism: 50-70% (CYP3A4); biliary/fecal: 10-20%.
Renal (80%) as inactive metabolites, 20% fecal via bile
Category C
Category C
Antihistamine
Antihistamine